A phase I clinical trial (NCT 02048709) was conducted to assess the curative effect and irAEs of the IDO-1 inhibitor navoximod in recurrent advanced solid tumors, but it failed to prove its effect in metastatic tumors, and thus, further investigation is warranted (75). The gene discussed is IDO1; the disease is metastatic neoplasm.